Protective effects of a coumarin derivative in diabetic rats

Investigative Ophthalmology and Visual Science

Volumn 50, Issue 8, 2009, Pages 3846-3852

  Bucolo, Claudio ^a   Ward, Keith W ^b   Mazzon, Emanuela ^c   Cuzzocrea, Salvatore ^c,d   Drago, Filippo ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b BAUSCH AND LOMB   (United States)

^c IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

^d UNIVERSITY OF MESSINA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; CLAUDIN 5; CLORICROMEN; COUMARIN DERIVATIVE; CYTOKINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EVANS BLUE; INTERCELLULAR ADHESION MOLECULE 1; OCCLUDIN; PEROXYNITRITE; PROTEIN ZO1; STREPTOZOCIN; TUMOR NECROSIS FACTOR ALPHA; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN; 3-NITROTYROSINE; 8-CHLOROCARBOCHROMEN; ANTITHROMBOCYTIC AGENT; CADHERIN; CARBOCROMEN; CLDN5 PROTEIN, RAT; DRUG DERIVATIVE; LEUKOCYTE ANTIGEN; MEMBRANE PROTEIN; NOS3 PROTEIN, RAT; PHOSPHOPROTEIN; TYROSINE; VASCULAR ENDOTHELIAL GROWTH FACTOR A, RAT; VASCULOTROPIN A; ZONULA OCCLUDENS 1 PROTEIN; ZONULA OCCLUDENS-1 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD RETINA BARRIER; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC RETINOPATHY; DRUG MECHANISM; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN LOCALIZATION; RAT; RETINA; STREPTOZOCIN DIABETES; TIGHT JUNCTION; TISSUE LEVEL; ANIMAL; DRUG EFFECT; EXPERIMENTAL DIABETES MELLITUS; INTRAPERITONEAL DRUG ADMINISTRATION; METABOLISM; PATHOLOGY; SPRAGUE DAWLEY RAT; WESTERN BLOTTING;

ANIMALS; ANTIGENS, CD; BLOOD-RETINAL BARRIER; BLOTTING, WESTERN; CADHERINS; CHROMONAR; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRAPERITONEAL; INTERCELLULAR ADHESION MOLECULE-1; MALE; MEMBRANE PROTEINS; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHOPROTEINS; PLATELET AGGREGATION INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; TUMOR NECROSIS FACTOR-ALPHA; TYROSINE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 68349104279     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.08-3328     Document Type: Article

References (29)

1. Limb GA, Chignell AH, Green W, LeRoy F, Dumonde DC. Distribution of TNF-alpha and its reactive vascular adhesion molecules in fibrovascular membranes of proliferative diabetic retinopathy. Br J Ophthalmol. 1996;80:168-173.
2. Limb GA, Soomro H, Janikoun S, Hollifield RD, Shilling J. Evidence for control of tumour necrosis factor-alpha (TNF-alpha) activity by TNF receptors in patients with proliferative diabetic retinopathy. Clin Exp Immunol. 1999;115:409-414.
3. Hawrami K, Hitman GA, Rema M, et al. An association in noninsulin-dependent diabetes mellitus subjects between susceptibility to retinopathy and tumor necrosis factor polymorphism. Hum Immunol. 1996;46:49-54.
4. Spranger J, Meyer-Schwickerath R, Klein M, Schatz H, Pfeiffer A. TNF-alpha level in the vitreous body. Increase in neovascular eye diseases and proliferative diabetic retinopathy. Med Klin. 1995;90: 134-137.
5. Kacimi R, Karliner JS, Koudssi F, Long CS. Expression and regulation of adhesion molecules in cardiac cells by cytokines: response to acute hypoxia. Circ Res. 1998;82:576-586.
6. Wright PS, Cooper JR, Kropp KE, Busch SJ. Induction of vascularcell adhesion molecule-1 expression by IL-4 in human aortic smooth muscle cells is not associated with increased nuclear NF-_B levels. J Cell Physiol. 1999;180:381-389.
7. Amrani Y, Lazaar AL, Panettieri RA. Up-regulation of ICAM-1 by cytokines in human tracheal smooth muscle cells involves an NF-kappa B-dependent signaling pathway that is only partially sensitive to dexamethasone. J Immunol. 1999;163:21-28.
8. Joussen AM, Poulaki V, Mitsiades N, et al. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-α suppression. FASEB J. 2002;16:438-440.
9. Romeo G, Liu WH, Asnaghi V, Kern TS, Lorenzi M. Activation of nuclear factor-kappaB induced by diabetes and high glucose regulates a proapoptotic program in retinal pericytes. Diabetes. 2002; 51:2241-2248.
10. Joussen AM, Poulaki P, Qin W, et al. Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo. Am J Pathol. 2002;160: 501-509.
11. Koto T, Takubo K, Ishida S, et al. Hypoxia disrupts the barrier function of neural blood vessels through changes in the expression of claudin-5 in endothelial cells. Am J Pathol. 2007;170:1389-1397.
12. Adamis AP. Is diabetic retinopathy an inflammatory disease? Br J Ophthalmol. 2002;16:363-365.
13. Joussen AM, Poulaki V, Le ML, et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J. 2004;18: 1450-1452.
14. McLeod DS, Lefer DJ, Merges C, Lutty GA. Enhanced expression of intracellular adhesion molecule-1 and P-selectin in the diabetic human retina and choroid. Am J Pathol. 1995;47:642-653.
15. Miyamoto K, Khosrof S, Bursell SE, et al. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci U S A. 1999;96:10836-10841.
16. Zheng L, Howell SJ, Hatala DA, Huang K, Kern TS. Salicylate-based anti-inflammatory drugs inhibit the early lesion of diabetic retinopathy. Diabetes. 2007;56:337-345.
17. Hoult JR, Payà M. Pharmacological and biochemical actions of simple coumarins: natural products with therapeutic potential. Gen Pharmacol. 1996;27:713-722.
18. Cuzzocrea S, Mazzon E, Bevilacqua C, et al. Cloricromene, a coumarine derivative, protects against collagen-induced arthritis in Lewis rats. Br J Pharmacol. 2000;131:1399-1407.
19. Frank RN. Etiologic mechanisms in diabetic retinopathy. In: Ryan SJ, Schachat AP, Murphy RP, Patz A, ed. Retina. St. Louis, Mosby; 1989:301-326.
20. Navaratna D, McGuire PG, Menicucci G, Das A. Proteolytic degradation of VE-cadherin alters the blood-retinal barrier in diabetes. Diabetes. 2007;56:2380-2387.
21. Barber AJ, Antonetti DA. Mapping the blood vessels with paracellular permeability in the retinas of diabetic rats. Invest Ophthalmol Vis Sci. 2003;44:5410-5416.
22. Antonetti DA, Barber AJ, Khin S, Lieth E, Tarbell JM, Gardner TW. Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: vascular endothelial growth factor decreases occludin in retinal endothelial cells. Penn State Retina Research Group. Diabetes. 1998;47:1953-1959.
23. Leal EC, Manivannan A, Hosoya K, et al. Inducible nitric oxide synthase isoform is a key mediator of leukostasis and blood-retinal barrier breakdown in diabetic retinopathy. Invest Ophthalmol Vis Sci. 2007;48:5257-5265.
24. Miyamoto K, Khosrof S, Bursell SE, et al. Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1). Am J Pathol.2000;156:1733-1739.
25. Giraudo E, Primo L, Audero E, et al. Tumor necrosis factor-alpha regulates expression of vascular endothelial growth factor receptor-2 and of its co-receptor neuropilin-1 in human vascular endothelial cells. J Biol Chem. 1998;273:22128-22135.
26. Ianaro A, Mafia P, Grassia G, et al. Cloricromene in endotoxemia: role of NF-kappaB. Naunyn Schmiedebergs Arch Pharmacol. 2004;370:140-145.
27. Fries W, Mazzon E, Sturiale S, et al. A protective effect of the synthetic coumarine derivative cloricromene against DNB-colitis in the rat. Life Sci. 2004;4:2749-2756.
28. Corsini E, Lucchi L, Binaglia M, et al. Cloricromene, a semi-syntheticcoumarin derivative, inhibits tumor necrosis factor-α production at a pre-transcriptional level. Eur J Pharmacol. 2001;418: 231-237.
29. Bucolo C, Cuzzocrea S, Mazzon E, Caputi AP. Effects of cloricromene, a coumarin derivative, on endotoxin-induced uveitis in Lewis rats. Invest Ophthalmol Vis Sci. 2003;44:1178-1184.